Retrospective study shows that early administration of convalescent plasma in hospitalized COVID-19 patients may have a positive effect on disease progression.
作者信息
Birschmann Ingvild, von Bargen Katharina, Teune Michelle, Flottmann Christian, Knüttgen Franziska, Knabbe Cornelius
机构信息
Herz- und Diabeteszentrum Nordrhein-Westfalen, Universitätsklinik der Ruhr-Universität Bochum Institut für Laboratoriums- und Transfusionsmedizin Bad Oeynhausen Germany.
Lukas Krankenhaus Bünde Medizinische Klinik II - Innere Medizin und Kardiologie Bünde Germany.
出版信息
Health Sci Rep. 2022 Aug 9;5(5):e714. doi: 10.1002/hsr2.714. eCollection 2022 Sep.
Abstract
摘要
相似文献
1
Retrospective study shows that early administration of convalescent plasma in hospitalized COVID-19 patients may have a positive effect on disease progression.
Health Sci Rep. 2022 Aug 9;5(5):e714. doi: 10.1002/hsr2.714. eCollection 2022 Sep.
2
Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Trials. 2021 May 17;22(1):343. doi: 10.1186/s13063-021-05181-0.
3
Endemic Human Coronavirus Antibody Levels Are Unchanged after Convalescent or Control Plasma Transfusion for Early Outpatient COVID-19 Treatment.
mBio. 2023 Feb 28;14(1):e0328722. doi: 10.1128/mbio.03287-22. Epub 2023 Jan 10.
4
A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.
Trials. 2020 Nov 27;21(1):981. doi: 10.1186/s13063-020-04876-0.
5
Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Trials. 2020 Jun 8;21(1):499. doi: 10.1186/s13063-020-04422-y.
6
Treatment of COVID-19 Patients with Two Units of Convalescent Plasma in a Resource-Constrained State.
Lab Med. 2022 Nov 3;53(6):623-628. doi: 10.1093/labmed/lmac055.
7
Utilization of the Abbott SARS-CoV-2 IgG II Quant Assay To Identify High-Titer Anti-SARS-CoV-2 Neutralizing Plasma against Wild-Type and Variant SARS-CoV-2 Viruses.
Microbiol Spectr. 2022 Oct 26;10(5):e0281122. doi: 10.1128/spectrum.02811-22. Epub 2022 Sep 20.
8
Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
Trials. 2021 May 17;22(1):342. doi: 10.1186/s13063-021-05189-6.
9
Limited Correlation between SARS-CoV-2 Serologic Assays for Identification of High-Titer COVID-19 Convalescent Plasma Using FDA Thresholds.
Microbiol Spectr. 2022 Aug 31;10(4):e0115422. doi: 10.1128/spectrum.01154-22. Epub 2022 Jul 5.
10
Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG.
Am J Pathol. 2021 Jan;191(1):90-107. doi: 10.1016/j.ajpath.2020.10.008. Epub 2020 Nov 4.
本文引用的文献
1
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19.
JAMA Oncol. 2021 Jun 17;7(8):1167-75. doi: 10.1001/jamaoncol.2021.1799.
2
Use of convalescent plasma in COVID-19 patients with immunosuppression.
Transfusion. 2021 Aug;61(8):2503-2511. doi: 10.1111/trf.16525. Epub 2021 Jun 1.
3
Convalescent plasma treatment of critically ill intensive care COVID-19 patients.
Transfusion. 2021 May;61(5):1394-1403. doi: 10.1111/trf.16392. Epub 2021 Apr 8.
4
Severe covid-19 pneumonia: pathogenesis and clinical management.
BMJ. 2021 Mar 10;372:n436. doi: 10.1136/bmj.n436.
5
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19.
N Engl J Med. 2021 Mar 18;384(11):1015-1027. doi: 10.1056/NEJMoa2031893. Epub 2021 Jan 13.
6
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.
N Engl J Med. 2021 Feb 18;384(7):610-618. doi: 10.1056/NEJMoa2033700. Epub 2021 Jan 6.
7
Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial).
BMJ. 2020 Oct 22;371:m3939. doi: 10.1136/bmj.m3939.
8
Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19.
Mol Cell Biochem. 2021 Feb;476(2):553-574. doi: 10.1007/s11010-020-03924-2. Epub 2020 Oct 7.
9
Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality.
Am J Pathol. 2020 Nov;190(11):2290-2303. doi: 10.1016/j.ajpath.2020.08.001. Epub 2020 Aug 11.
10
Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study.
Transfus Apher Sci. 2020 Oct;59(5):102875. doi: 10.1016/j.transci.2020.102875. Epub 2020 Jul 15.
Zotero 插件